Cogent’s CGT1145 Hits 100x JAK2 Selectivity, IND Filing Next for Rare Cancer Drug

For biopharma investors and R&D strategists, the compelling selectivity data for CGT1145 validate the concept of allosteric JAK2 inhibition and position Cogent to challenge entrenched therapies like ruxolitinib in a market worth billions. The 100-fold window over wild-type JAK2 suggests a scalable safety advantage that, if replicated in the clinic, could make CGT1145 the backbone of future myelofibrosis combination regimens.

Cogent Biosciences (NASDAQ:COGT) unveiled early-stage preclinical data for its novel JAK2 inhibitor, CGT1145, at the European Hematology Association Congress on June 12, 2026. The centerpiece of the announcement was a remarkable selectivity profile: CGT1145 exhibited over 100-fold preference for the JAK2 V617F mutant form over the wild-type JAK2 protein and related JAK1/3 isoforms. This level of precision is not an incremental improvement; it directly addresses a fundamental limitation of current standard-of-care JAK inhibitors like ruxolitinib (Jakafi), which bind non-selectively to both mutant and normal JAK2, causing on-target toxicities such as thrombocytopenia and anemia that frequently lead to dose reductions and compromised outcomes. CGT1145, by sparing wild-type JAK2, could maintain robust therapeutic pressure on malignant clones while preserving normal hematopoietic function.

“

From a commercial and clinical standpoint, the myelofibrosis market alone is projected to exceed several billion dollars globally, with ruxolitinib generating over $2 billion annually.

The drug is designed for rare myeloproliferative neoplasms—principally myelofibrosis, polycythemia vera, and essential thrombocythemia—all driven by the JAK2 V617F mutation in a significant proportion of patients. Current JAK inhibitors provide symptomatic relief and spleen size reduction but rarely achieve molecular remission, because they suppress the downstream signaling rather than eradicating the disease-causing cells. Cogent’s preclinical data suggest that CGT1145 may actually eliminate the driver cells, a feature that could translate into molecular remission—a long-sought goal in this field. The compound also demonstrated strong oral bioavailability and consistent behavior across different biologic assays, indicating a favorable pharmacokinetic profile well-suited for chronic oral dosing.

From a commercial and clinical standpoint, the myelofibrosis market alone is projected to exceed several billion dollars globally, with ruxolitinib generating over $2 billion annually. A drug that offers disease modification without dose-limiting cytopenias could rapidly capture significant share and expand the treatment population to patients who currently cannot tolerate existing therapies. Cogent’s broader pipeline, including its lead asset bezuclastinib for KIT-mutated cancers, provides a foundation of kinase inhibitor expertise and a diversified risk profile.